Overview
Drugs - Real World Outcomes targets research involving the use of real-world data to evaluate health outcomes and inform healthcare decision-making, with a particular focus on healthcare-related 'big data'. Drugs - Real World Outcomes has a broad scope, encompassing studies investigating drug utilisation, patterns of prescribing, pharmacovigilance, treatment guideline adherence, benefit-risk assessments, comparative effectiveness and economic analyses.
Manuscripts accepted for publication by the journal are subject to an article processing charge (APC). Details of the current APC and open access funding and support services are available here.
Drugs - Real World Outcomes offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content (more information).
- Editor-in-Chief
-
- Dene Peters
- Associate Editor
-
- Sophie Stevenson
- Impact factor
- 2.0 (2022)
- Submission to first decision (median)
- 7 days
- Downloads
- 376,357 (2023)
Latest articles
Journal updates
-
Digital Features
Drugs - Real World Outcomes is able to host a range of digital features, with a number of options available to authors.
Journal information
- Electronic ISSN
- 2198-9788
- Abstracted and indexed in
-
- BIOSIS
- Baidu
- Biological Abstracts
- CLOCKSS
- CNKI
- CNPIEC
- DOAJ
- Dimensions
- EBSCO
- EMBASE
- EMCare
- Emerging Sources Citation Index
- Gale
- Google Scholar
- Naver
- Norwegian Register for Scientific Journals and Series
- OCLC WorldCat Discovery Service
- Portico
- ProQuest
- PubMedCentral
- SCImago
- SCOPUS
- Semantic Scholar
- TD Net Discovery Service
- UGC-CARE List (India)
- Wanfang
- Copyright information